Borgeson Blake 4

What Happened
Blake Borgeson, a director of Recursion Pharmaceuticals, sold 30,000 shares in an open-market transaction on April 7, 2026, at $3.10 per share, generating proceeds of approximately $93,000. The filing lists the disposition code S (sale).

Key Details

• Transaction date: April 7, 2026; Filing date: April 8, 2026 (appears timely).
• Price and proceeds: 30,000 shares × $3.10 = $93,000 (gross).
• Shares owned after transaction: not specified in the provided filing.
• Footnote: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted August 31, 2025 (prearranged plan).
• Transaction type: Open-market sale (disposition).

Context
A 10b5-1 plan allows insiders to execute prearranged trades at scheduled times and is commonly used to avoid questions about trading on material nonpublic information. Sales under such plans are often routine and do not by themselves indicate a change in the insider’s view of the company.